Unresectable intrahepatic cholangiocarcinoma
Conditions
Brief summary
Progression-free survival
Detailed description
1. Compare the overall survival in first-line HAI FUDR/Dex in combination with GemOx versus systemic GemOx only., 2. Estimate the overall response rate (CR+PR) between treatment groups., 3. Estimate the time to first recurrence patterns between treatment groups., 4. Describe the toxicity rates separately for each treatment groups., Define the mutational pattern of IHC and determine the extent to which genomic features and intratumoral heterogeneity correlate with treatment response and survival.
Interventions
DRUG-
Sponsors
Memorial Sloan Kettering Cancer Center
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| 1. Compare the overall survival in first-line HAI FUDR/Dex in combination with GemOx versus systemic GemOx only., 2. Estimate the overall response rate (CR+PR) between treatment groups., 3. Estimate the time to first recurrence patterns between treatment groups., 4. Describe the toxicity rates separately for each treatment groups., Define the mutational pattern of IHC and determine the extent to which genomic features and intratumoral heterogeneity correlate with treatment response and survival. | — |
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival | — |
Countries
Netherlands
Outcome results
None listed